MX2024006393A - Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab. - Google Patents

Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab.

Info

Publication number
MX2024006393A
MX2024006393A MX2024006393A MX2024006393A MX2024006393A MX 2024006393 A MX2024006393 A MX 2024006393A MX 2024006393 A MX2024006393 A MX 2024006393A MX 2024006393 A MX2024006393 A MX 2024006393A MX 2024006393 A MX2024006393 A MX 2024006393A
Authority
MX
Mexico
Prior art keywords
demyelinating disease
cns
treatment
nervous system
central nervous
Prior art date
Application number
MX2024006393A
Other languages
English (en)
Spanish (es)
Inventor
Takatoshi Ozawa
Hajime Ito
Shunsuke Yoshida
Jillian Smith
Sian Lennon-Chrimes
Baumann Hanna Silber
Mai Yamashiro
Ivana Vodopivec
Gaelle Klingelschmitt
Buedingen Hans-Christian Von
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2024006393A publication Critical patent/MX2024006393A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024006393A 2021-11-26 2022-10-25 Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab. MX2024006393A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2021/043459 WO2023095305A1 (en) 2021-11-26 2021-11-26 Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
PCT/JP2022/039605 WO2023095510A1 (en) 2021-11-26 2022-10-25 Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab

Publications (1)

Publication Number Publication Date
MX2024006393A true MX2024006393A (es) 2024-06-04

Family

ID=86539186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006393A MX2024006393A (es) 2021-11-26 2022-10-25 Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab.

Country Status (10)

Country Link
US (1) US20250034265A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543147A (cg-RX-API-DMAC7.html)
KR (1) KR20240107372A (cg-RX-API-DMAC7.html)
CN (1) CN118591389A (cg-RX-API-DMAC7.html)
AU (1) AU2022398430A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238940A1 (cg-RX-API-DMAC7.html)
IL (1) IL313058A (cg-RX-API-DMAC7.html)
MX (1) MX2024006393A (cg-RX-API-DMAC7.html)
TW (1) TW202330030A (cg-RX-API-DMAC7.html)
WO (3) WO2023095305A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010065116A2 (en) 2008-12-02 2010-06-10 The Trustees Of The University Of Pennsylvania The use of il-27-p28 to antagonize il-6 mediated signaling
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途

Also Published As

Publication number Publication date
WO2023095852A1 (en) 2023-06-01
WO2023095510A1 (en) 2023-06-01
CA3238940A1 (en) 2023-06-01
CN118591389A (zh) 2024-09-03
JP2024543147A (ja) 2024-11-19
US20250034265A1 (en) 2025-01-30
WO2023095305A1 (en) 2023-06-01
IL313058A (en) 2024-07-01
KR20240107372A (ko) 2024-07-09
TW202330030A (zh) 2023-08-01
AU2022398430A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
EP4706763A3 (en) Anti-c5 antibodies and uses thereof
PH12020500643A1 (en) Anti-ngf antibodies and methods thereof
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
CR20220660A (es) Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
MX2025012052A (es) Molecula de union a antigeno que se une especificamente a egfr y muc1, conjugado farmaceutico del mismo y uso medico del mismo
ATE461220T1 (de) Anti-egfr-antikörper
MX2010003380A (es) Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina.
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
MX2025004652A (es) Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos
PH12022500030A1 (en) Anti-tgf㟠antibodies and therapeutic uses thereof
NZ595005A (en) Treatment of insulin-resistant disorders
MX2021005323A (es) Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn.
MX2024002711A (es) Anticuerpos de receptor de activina tipo-2a (anti-acvr2a) y usos de estos.
CA3242378A1 (en) Anti-musk antibodies for use in treating neuromuscular disorders
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
CR20230528A (es) Anticuerpo anti componente del complemento 1s (c1s)
MX2023004020A (es) Anticuerpos anti-ngf y métodos para su uso.
MY210018A (en) Monoclonal antibody that binds specifically to gitr
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
PH12022552741A1 (en) Anti-ox40 antibody and uses thereof
MX2025003153A (es) Anticuerpos anti-ccr8
MX2024014232A (es) Anticuerpo anti-b7h3 y usos del mismo
MX2025011061A (es) Union de anticuerpos al dominio similar a la proteasa del receptor de transferrina humano htfr1
MX2026000793A (es) Anticuerpo muc1 humanizado y conjugado anticuerpo-farmaco